Research
Hormonal
Weekly subcutaneous semaglutide (2.4 mg) produces significant weight loss (approx. 15%) and improves cardiovascular outcomes in adults with overweight or obesity, including those with heart failure with preserved ejection fraction (HFpEF).
If you have obesity, weekly semaglutide injections (2.4 mg) can help you lose about 15% of your body weight and significantly lower your risk of heart problems. This treatment is safe and effective for long-term use, unlike older drugs that were banned for causing heart issues.
StrongSupportsVERY_HIGH confidence
Incretin-based obesity treatments are making remarkable progress... significantly improving complications associated with obesity, such as cardiovascular diseases... Semaglutide 2.4 mg... showed a 15.2% weight loss... and the SELECT study demonstrated a 20% reduction in major cardiovascular events.
Why this rating
Based on multiple large-scale Phase 3 trials (STEP 1-8, SELECT) with robust statistical significance.
Source
Recent Progression of Incretin-Based Obesity Treatment
Dughyun Choi · Korean Journal of Medicine · 2024
narrative_review
Read the paper This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →